Trial Information

Summary: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Status: Completed

Protocol Number: NO16007

Sponsor: Hoffmann-La Roche Inc

Company Division: Pharmaceutical

Official Scientific Title: A randomized, open-label, dose finding study of the effect of subcutaneous administration of PEGASYS on tumor response in patients with metastatic malignant melanoma.

Brief Summary: This study will evaluate the safety and efficacy of different doses of PEGASYS in patients with metastatic malignant melanoma. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals. Target sample size is 135.

Study Phase: II

Study Design / Study Details:

• Purpose: Treatment
• Allocation: Non-Randomized
• Masking: Open Label
• Control: Uncontrolled
• Assignment: Parallel
• Endpoints: Safety/Efficacy

Study Type:

Condition: Malignant Melanoma

Intervention Type: Drug

Intervention Name: peginterferonalfa-2a (40KD) [PEGASYS]

Primary Outcome: 1. Efficacy: Measurements of visible and palpable tumor, disease response

Key Secondary Outcomes: 1. Safety: AEs, laboratory tests results, vital signs

Inclusion Criteria:

Exclusion Criteria:

Gender: Males or Females

Age Limits: Min: 18 Years Max: 75 Years

Accepts Healthy Volunteers: No

Trial Registration Date: 07/26/2005

Date Last Updated: 08/18/2008

Link To Trial Results

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: September 2, 2008 at 1:47:44 PM